Market closedNon-fractional
Relmada Therapeutics/RLMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Relmada Therapeutics
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Ticker
RLMD
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Coral Gables, United States
Employees
20
Website
www.relmada.com
RLMD Metrics
BasicAdvanced
$122M
Market cap
-
P/E ratio
-$3.13
EPS
0.27
Beta
-
Dividend rate
Price and volume
Market cap
$122M
Beta
0.27
Financial strength
Current ratio
6.825
Quick ratio
6.764
Management effectiveness
Return on assets (TTM)
-55.99%
Return on equity (TTM)
-95.48%
Valuation
Price to book
1.71
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
-2.53
Growth
Earnings per share change (TTM)
-34.45%
3-year earnings per share growth (CAGR)
-10.87%
What the Analysts think about RLMD
Analyst Ratings
Majority rating from 5 analysts.
RLMD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
-13.15%
Profit margin
0.00%
NaN%
RLMD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.84
-$0.73
-$0.84
-$0.72
-
Expected
-$0.90
-$0.91
-$0.83
-$0.85
-$0.83
Surprise
-6.34%
-20.04%
1.20%
-15.23%
-
RLMD News
AllArticlesVideos
Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue
Accesswire·7 hours ago
Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue
Accesswire·1 day ago
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
PRNewsWire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Relmada Therapeutics stock?
Relmada Therapeutics (RLMD) has a market cap of $122M as of July 27, 2024.
What is the P/E ratio for Relmada Therapeutics stock?
The price to earnings (P/E) ratio for Relmada Therapeutics (RLMD) stock is 0 as of July 27, 2024.
Does Relmada Therapeutics stock pay dividends?
No, Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Relmada Therapeutics dividend payment date?
Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Relmada Therapeutics?
Relmada Therapeutics (RLMD) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Relmada Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.